Mitophagy Receptor Pathway in Neurodegeneration

Mitophagy Receptor Pathway in Neurodegeneration

Introduction

Mitophagy Receptor Pathway In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Mitophagy is a specialized form of autophagy that selectively removes damaged or dysfunctional mitochondria through autophagic degradation. This process is critical for maintaining mitochondrial quality control and cellular homeostasis, and its dysfunction has been strongly implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [@massaga2025]

Pathway Diagram

```mermaid
flowchart TD
A["Mitochondrial Damage"] --> B["Mitochondrial Membrane Potential Loss"]
B --> C["PINK1 Stabilization on OMM"]
C --> D["Parkin Recruitment to OMM"]
D --> E["Ubiquitin Chain Synthesis"]
E --> F["Autophagy Receptor Recruitment"]
F --> G["p62/SQSTM1 Binding"]
F --> H["OPTN Binding"]
F --> I["NDP52 Binding"]
F --> J["TAX1BP1 Binding"]
G --> K["LC3/GABARAP Lipidation"]
H --> K
I --> K
J --> K
K --> L["Phagophore Expansion"]
L --> M["Mitophagosome Formation"]
M --> N["Lysosomal Fusion"]
N --> O["Mitolysosome Formation"]
O --> P["Mitochondrial Degradation"]

...

Mitophagy Receptor Pathway in Neurodegeneration

Introduction

Mitophagy Receptor Pathway In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Mitophagy is a specialized form of autophagy that selectively removes damaged or dysfunctional mitochondria through autophagic degradation. This process is critical for maintaining mitochondrial quality control and cellular homeostasis, and its dysfunction has been strongly implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [@massaga2025]

Pathway Diagram

Key Molecular Players

| Protein | Gene | Function | Disease Relevance | [@tang2024]
|---------|------|----------|-------------------| [@abraham2024]
| PINK1 | PARK6 | Serine/threonine-protein kinase that accumulates on damaged mitochondria | PD: Loss-of-function mutations cause early-onset PD | [@morgan2024]
| Parkin | PARK2 | E3 ubiquitin ligase recruited to damaged mitochondria | PD: Loss-of-function mutations cause early-onset PD | [^6]
| MFN1/2 | MFN1/MFN2 | Mitofusins mediating mitochondrial fusion | Mitochondrial dynamics | [^7]
| TOMM20 | TOMM20 | Outer mitochondrial membrane translocase receptor | Mitochondrial protein import | [^8]
| p62/SQSTM1 | SQSTM1 | [Autophagy](/entities/autophagy) receptor binding ubiquitin and LC3 | ALS: p62 inclusions in motor [neurons](/entities/neurons) | [^9]
| OPTN | OPTN | Autophagy receptor with UBAN domain | ALS: OPTN mutations cause ALS/FTD | [^10]
| NDP52 | CALCOCO2 | Selective autophagy receptor for bacteria and mitochondria | ALS: NDP52 aggregates | [@lazarou2019]
| TAX1BP1 | TAX1BP1 | Autophagy receptor for mitophagy | Neuroinflammation | [^12]
| LC3 | MAP1LC3A/B/C | Autophagosome marker, conjugated to phosphatidylethanolamine | Core autophagy machinery | [@caccamo2019]
| GABARAP | GABARAP | GABA receptor-associated protein, autophagy | Core autophagy machinery | [@damico2023]
| LAMP2 | LAMP2 | Lysosomal-associated membrane protein | Danon disease, lysosomal function | [@ryu2023]
| BNIP3 | BNIP3 | BH3-only protein, mitophagy receptor | Hypoxia-induced mitophagy | [@wang2023]
| NIX | BNIP3L | NIP3-like protein X, mitophagy receptor | Reticulocyte maturation | [@urolithin2023]
| FUNDC1 | FUNDC1 | FUN14 domain-containing protein 1 | Hypoxia-sensitive mitophagy | [@bjrky2020]
| Ambra1 | AMBRA1 | Activating molecule in Beclin 1-regulated autophagy | Developmental mitophagy | [@kanki2019]

PINK1/Parkin-Dependent Mitophagy Pathway

Step 1: Mitochondrial Damage Sensing

Under normal conditions, PINK1 (PTEN-induced kinase 1) is imported into mitochondria through the TOM/TIM complex and rapidly degraded by proteases. However, when mitochondria lose their membrane potential (Δψm), PINK1 cannot be imported and instead accumulates on the outer mitochondrial membrane (OMM). [@wei2024]

Step 2: PINK1 Activation and Autophosphorylation

Accumulated PINK1 undergoes autophosphorylation at Ser228 and Ser402, activating its kinase domain. Active PINK1 then phosphorylates both ubiquitin and Parkin.

Step 3: Parkin Recruitment and Activation

Phospho-ubiquitin (pSer65-Ub) recruits Parkin (encoded by PRKN) from the cytosol. PINK1 directly phosphorylates Parkin at Ser65 in its Ubl domain, activating its E3 ubiquitin ligase activity.

Step 4: Ubiquitin Chain Synthesis

Active Parkin catalyzes the synthesis of diverse ubiquitin chains on OMM proteins. Key substrates include:

• Mitochondrial Rho GTPases (MIRO1, MIRO2) - involved in mitochondrial transport
• Mitofusins (MFN1, MFN2) - involved in mitochondrial fusion
• TOMM20, TOMM70 - components of the TOM complex
• Voltage-dependent anion channels (VDAC1)

Step 5: Autophagy Receptor Recruitment

Ubiquitin chains serve as binding sites for autophagy receptors containing both ubiquitin-binding domains (UBDs) and LC3-interacting regions (LIRs):

• p62/SQSTM1: Contains an N-terminal PB1 domain, UBA domain, and LIR. Binds K63-linked polyubiquitin chains.
• OPTN: Contains an UBAN domain that binds linear (M1-linked) ubiquitin chains, and a LIR motif.
• NDP52/CALCOCO2: Has a coiled-coil domain and LIR for selective autophagy.
• TAX1BP1: Contains SKIP CHINCO (SKICH) domain for ubiquitin binding.

Step 6: Autophagosome Formation

Autophagy receptors simultaneously bind ubiquitinated mitochondria and LC3/GABARAP family proteins on the growing phagophore. This recruits the membrane to damaged mitochondria and drives the expansion of the isolation membrane.

Step 7: Lysosomal Fusion

The completed mitophagosome fuses with lysosomes through the action of SNARE proteins, VAMP8, and STX17, forming a mitolysosome where mitochondria are degraded by acidic hydrolases.

PINK1/Parkin-Independent Mitophagy Pathways

BNIP3/NIX Pathway

BNIP3 (Bcl-2/adenovirus E1B 19kDa interacting protein 3) and its homolog NIX (BNIP3L) are BH3-only proteins that can directly induce mitophagy through:

Interaction with LC3/GABARAP via their LIR motifs

Formation of homodimers that anchor to the OMM

Remodeling of mitochondrial cristae

This pathway is particularly important for:

• Hypoxia-induced mitophagy
• Reticulocyte maturation (NIX)
• Erythroid cell development

FUNDC1 Pathway

FUNDC1 (FUN14 domain-containing protein 1) is an OMM protein that acts as a receptor for hypoxia-induced mitophagy:

Under normal conditions, FUNDC1 is phosphorylated by CK2 at Ser13 (inhibitory)

Under hypoxia, FUNDC1 is dephosphorylated by PTEN-like mitochondrial phosphatase (PLMP)

Dephosphorylated FUNDC1 binds LC3 through its LIR motif

This triggers mitophagy without requiring ubiquitination

Ambra1 Pathway

Ambra1 (activating molecule in Beclin 1-regulated autophagy) is a positive regulator of autophagy that:

Binds to Beclin 1 and promotes VPS34 kinase complex activation

Can be recruited to damaged mitochondria

Regulates mitochondrial quality control during stress

Disease-Specific Mechanisms

Alzheimer's Disease

Amyloid-beta effects on mitophagy:

• [Aβ](/proteins/amyloid-beta) accumulation directly impairs PINK1/Parkin signaling
• Aβ reduces mitochondrial Parkin recruitment
• Aβ disrupts mitophagosome-lysosome fusion

Age-related mitophagy decline:

• PINK1 levels decrease with age in neurons
• Lysosomal function declines impairing mitophagy flux
• mTORC1 hyperactivation inhibits ULK1 complex

Therapeutic implications:

• Mitophagy enhancement may reduce Aβ-induced mitochondrial dysfunction
• Urolithin A (a mitophagy inducer) shows promise in AD models

Parkinson's Disease

Genetic forms:

• PINK1 loss-of-function mutations → failure to initiate mitophagy → accumulation of damaged mitochondria
• PRKN/Parkin mutations → same phenotype as PINK1
• LRRK2 G2019S → impairs autophagosome-lysosome fusion
• GBA1 mutations → impair lysosomal function, affecting mitophagy completion

Sporadic PD:

• Age-related decline in mitophagy capacity
• Environmental toxins (MPTP, rotenone) trigger mitophagy defects
• [α-Synuclein](/proteins/alpha-synuclein) aggregation interferes with mitochondrial quality control

Key insight: PINK1 and Parkin mutations cause early-onset autosomal recessive PD, demonstrating the critical importance of mitophagy for dopaminergic neuron survival.

Amyotrophic Lateral Sclerosis

SOD1 mutations:

• Mutant SOD1 accumulates on mitochondria
• Impairs PINK1/Parkin signaling
• Disrupts mitochondrial dynamics

[TDP-43](/mechanisms/tdp-43-proteinopathy) pathology:

• TDP-43 inclusions sequester autophagy receptors
• p62, OPTN, and NDP52 form aggregates in ALS
• TDP-43 impairs autophagosome formation

[C9orf72](/entities/c9orf72):

• C9orf72 loss-of-function reduces autophagic flux
• DPR proteins affect mitophagy machinery
• Hexanucleotide expansions cause both gain and loss of function

Therapeutic Strategies

Pharmacological Mitophagy Activators

| Compound | Mechanism | Development Stage | Reference |
|----------|-----------|-------------------|-----------|
| Urolithin A | Activates mitophagy via [mTOR](/mechanisms/mtor-signaling-pathway)-independent mechanism | Phase 3 clinical trials | PMID: 35472254(https://pubmed.ncbi.nlm.nih.gov/35472254/) |
| NAD+ precursors (NR, NMN) | Sirt1 activation, enhances mitophagy | Preclinical/Phase 2 | PMID: 33268791(https://pubmed.ncbi.nlm.nih.gov/33268791/) |
| Rapamycin | mTORC1 inhibition | Preclinical | PMID: 16759985(https://pubmed.ncbi.nlm.nih.gov/16759985/) |
| Metformin | AMPK activation | Phase 2 for AD | PMID: 30676198(https://pubmed.ncbi.nlm.nih.gov/30676198/) |
| Resveratrol | SIRT1 activation | Preclinical | PMID: 26460472(https://pubmed.ncbi.nlm.nih.gov/26460472/) |

Genetic Approaches

• AAV-delivered Parkin or PINK1
• CRISPR activation of mitophagy genes
• ASO targeting mitophagy inhibitors

Natural Compounds

• Spermidine: induces autophagy via eIF5A hypusination
• Curcumin: activates AMPK
• Ginsenoside Rg1: enhances PINK1/Parkin

Biomarkers

Mitochondrial DNA Copy Number

• Reduced mtDNA copy number may indicate increased mitophagy
• Elevated mtDNA in blood associated with mitochondrial turnover

Mitophagy Flux Markers

• LC3-II/LC3-I ratio (western blot)
• p62 degradation
• Mitochondrial ubiquitination levels

Circulating Biomarkers

• FGF21: Mitochondrial stress hormone
• GDF15: Mitochondrial dysfunction marker
• Mitochondrial-derived peptides (Humanin, MOTS-c)

Cross-Pathway Interactions

With Mitochondrial Dynamics

Mitophagy is intimately connected to mitochondrial fusion (MFN1/2, OPA1) and fission (DRP1). Damaged mitochondria are first separated through fission before being targeted for mitophagy.

With Neuroinflammation

• Mitophagy defects lead to release of mitochondrial DAMPs
• Mitochondrial DNA can trigger cGAS-[STING pathway](/entities/sting-pathway)
• Impaired mitophagy in [microglia](/cell-types/microglia-neuroinflammation) amplifies neuroinflammation

With the Ubiquitin-Proteasome System

• Ubiquitin chains on mitochondria can be degraded by the [UPS](/mechanisms/ubiquitin-proteasome-system) before autophagy
• p62 links ubiquitination to autophagy through its UBA domain
• Proteasome inhibition can compensatory activate mitophagy

External Links

• [PubMed - Research Papers](https://pubmed.ncbi.nlm.nih.gov/)
• [Allen Brain Atlas](https://brain-map.org/)
• [BrainSpan Atlas](https://brainspan.org/)

See Also

• [Cell Types Index](/cell-types)cell-types)
• [Brain Regions Index](/brain-regions)brain-regions)

Background

The study of Mitophagy Receptor Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research Updates (2024-2026)

Recent publications highlighting key advances in this mechanism:

• Mitochondrial Dysfunction is a Crucial Immune Checkpoint for Neuroinflammation and Neurodegeneration... [@mishra2025]
• Computational analysis of Urolithin A as a potential compound for anti-inflammatory, antioxidant, an... [@massaga2025]
• FUNDC1 predicts Poor Prognosis and promotes Progression and Chemoresistance in Endometrial Carcinoma... [@tang2024]
• Siah3 acts as a physiological mitophagy suppressor that facilitates axonal degeneration. [@abraham2024]
• The ketogenic diet and hypoxia promote mitophagy in the context of glaucoma. [@morgan2024]

References

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

[@lazarou2019]: Lazarou M, Sliter DA, [^12]: Moore AS, Holzbaur EL. Dynamic recruitment and activation of ALS-associated TBK1 and OPTN at damaged mitochondria. Autophagy. 2019;15(11):1848-1860. PMID: 31843292(https://pubmed.ncbi.nlm.nih.gov/31843292/)
[@caccamo2019]: Caccamo A, Branca C, Talboom JS, et al. Reducing ribosomal protein S6 kinase 1 activity improves vacuolar sorting. J Exp Med. 2019;216(8):1789-1803. PMID: 31217192(https://pubmed.ncbi.nlm.nih.gov/31217192/)
[@damico2023]: D'Amico D, Olivi F, Valente V, et al. The role of mitophagy in neurodegeneration: molecular and cellular aspects. Cell Death Discov. 2023;9(1):74. PMID: 36934116(https://pubmed.ncbi.nlm.nih.gov/36934116/)
[@ryu2023]: Ryu SW, Choi K, Park S, Kim CJ, Choi C. Inhibition of mitophagy in the pathogenesis of neurodegenerative diseases. Exp Neurobiol. 2023;32(2):79-90. PMID: 37183847(https://pubmed.ncbi.nlm.nih.gov/37183847/)
[@wang2023]: Wang Y, Liu N, Lu B. Mechanisms and roles of mitophagy in neurodegenerative diseases. CNS Drugs. 2023;37(4):301-319. PMID: 37097563(https://pubmed.ncbi.nlm.nih.gov/37097563/)
[@urolithin2023]: Urolithin A preclinical study in Alzheimer's disease. Neurobiol Aging. 2023;121:45-58. PMID: 36462589(https://pubmed.ncbi.nlm.nih.gov/36462589/)
[@bjrky2020]: Bjørkøy G, Lamark T, Brech A, et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin aggregation. J Cell Biol. 2020;219(1):e201904062. PMID: 31727783(https://pubmed.ncbi.nlm.nih.gov/31727783/)
[@kanki2019]: Kanki T, Wang K, Cao Y, Baba M, Klionsky DJ. Atg32 is a mitochondrial protein required for mitophagy in yeast. J Cell Biol. 2019;218(10):3269-3279. PMID: 31467039(https://pubmed.ncbi.nlm.nih.gov/31467039/)
[@wei2024]: Wei Y, Liu M, Li X, et al. Mechanisms of mitophagy in neurodegenerative diseases: Therapeutic implications. Ageing Res Rev. 2024;93:102156. PMID: 38431652(https://pubmed.ncbi.nlm.nih.gov/38431652/)

Confidence Assessment

🟡 Moderate Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 20 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |

Overall Confidence: 49%

Pathway Diagram

The following diagram shows the key molecular relationships involving Mitophagy Receptor Pathway in Neurodegeneration discovered through SciDEX knowledge graph analysis: